Navigation Links
Pharmasset to Webcast an Investor Event from the AASLD Meeting
Date:10/27/2010

n unpartnered guanosine nucleotide analog in a Phase 1 study. We also have in our pipeline an additional purine nucleotide analog, PSI-661, in advanced preclinical development. Racivir, for the treatment of HIV, has completed a Phase 2 clinical study.

Pegasys® and Copegus® are registered trademarks of Roche. ContactRichard E. T. Smith, Ph.D.VP, Investor Relations and Corporate CommunicationsOffice: +1 (609) 613-4181Forward-Looking StatementsPharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:  Statements in this press release that are not historical facts are "forward-looking statements," that involve risks, uncertainties, and other important factors, including, without limitation,  the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates,  the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized.  For a discussion of risks, uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2009 and our Quarterly Reports on Form 10-Q for the periods ended December 31, 2009, March 31, 2010 and June 30, 2010 filed with the Securities and Exchange Commission and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission.
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset to Present at the JMP Healthcare Conference
2. Pharmasset to Present at the UBS Global Life Sciences Conference
3. Pharmasset Initiates Phase 2b Clinical Trial of PSI-7977 for Chronic Hepatitis C Genotypes 1, 2, and 3
4. Pharmasset to Present at the 28th Annual JPMorgan Healthcare Conference
5. Pharmasset Reports Fiscal Year End 2009 Financial Results
6. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
7. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
8. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
9. Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
10. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
11. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... September 18, 2014 According ... (Surface & Intravascular Systems- Warming & Cooling), Application ... (Surgeon & Anesthesiologist, Nursing & Paramedical Staff) - ... MarketsandMarkets, this report studies the global Temperature Management Market ... The market is expected to reach $2.5 Billion ...
(Date:9/18/2014)... SAN ANTONIO, Texas , Sept. 18, 2014  Casen ... vessels, skin and muscles to harden.  His case is one ... (GVM) in the world.  The only hospital in ... few in the world, offering treatment with the dual wave-length ... in San Antonio . Using a laser ...
(Date:9/18/2014)... , Sept. 18, 2014 Research ... "China PTCA Balloon Market Investment Report, 2014-2016" ... as a indispensable medical device in percutaneous coronary intervention ... stent, but also as a device for pre-/post-stent dilatations. ... related to that of PCI. As national ...
Breaking Medicine Technology:Temperature Management Market Worth $2.5 Billion by 2019 2Temperature Management Market Worth $2.5 Billion by 2019 3Temperature Management Market Worth $2.5 Billion by 2019 4Methodist Children's Hospital In San Antonio, TX Only Hospital In The U.S. Treating Rare Vascular Condition With Dual Wave-Length Laser 2China PTCA Balloon Market Investment Report, 2014-2016 2China PTCA Balloon Market Investment Report, 2014-2016 3
... Medical Systems, a global developer of high-end ultrasound systems, ... number of clinical applications and ranked first or second ... KLAS  "Ultrasound 2011: Innovation on the Move" report. ... monitoring and reporting the performance of information technology and ...
... Suneva Medical, a privately-held aesthetic medical device ... aesthetics injectable business with approval from Health Canada ... dermal filler for nasolabial folds or smile line ... long-lasting treatment, Bellafill provides physicians the opportunity to ...
Cached Medicine Technology:ZONARE Scores in Clinical Applications, Performance and Customer Support & Service in KLAS 2011 Ultrasound Report 2ZONARE Scores in Clinical Applications, Performance and Customer Support & Service in KLAS 2011 Ultrasound Report 3Suneva Medical Announces Canadian Approval of Bellafill™ 2
(Date:9/18/2014)... Sunnyvale, California (PRWEB) September 18, 2014 ... Dr. Ellen Brown to the position of Chief Medical ... as Medical Director for several Pathways programs including Pathways ... for patients in San Mateo and Santa Clara Counties. ... for the medical component of Pathway’s patient care program. ...
(Date:9/18/2014)... of the fight for superiority between mutated genes and ... leukaemia, say researchers from the University of Birmingham and ... Reports , investigated Acute Myeloid Leukaemia to understand why ... mature blood cells. , Stem cells in the bone ... The process resembles a production line with genes acting ...
(Date:9/18/2014)... . In ecology, disease ... pathogen tooth and nail, but rather tolerate it to live (and ... is that the disease only progresses very slowly if at ... , Roland Regoes, a senior scientist at ETH Zurich,s Institute of ... about investigating whether there are infected people who are more tolerant ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Clinical trial ... data on the Edema clinical trial scenario. This report ... trials on Edema. It includes an overview of the ... site of trial conduction across the globe. The databook ... their phase, trial status, prominence of the sponsors and ...
(Date:9/18/2014)... September 18, 2014 This past August, Narconon ... from Roy at the kissing booth during the West Feliciana Animal ... Shelter. “I have loved animals my whole life and have ... those animals being strays who needed a home. Supporting an ... can’t take them all home!” , The CEO of Narconon Louisiana ...
Breaking Medicine News(10 mins):Health News:Dr. Ellen Brown Promoted to Chief Medical Director at Pathways Home Health & Hospice 2Health News:The war on leukemia: How the battle for cell production could be decisive 2Health News:Withdrawal from the evolutionary race 2Health News:Withdrawal from the evolutionary race 3Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 2Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 3Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 4Health News:Narconon New Life Retreat Supports Local Animal Shelter At Recent Fundraiser 2
... set by CDC need to be lowered, experts say , ... levels well below those considered safe are still at risk ... , Currently, the maximum safe blood level of lead is ... the U.S. Centers for Disease Control and Prevention in 1991. ...
... ... of the advisory board for PerfectServe, a healthcare communications company. , ... Knoxville, TN (PRWeb) Sept. 17, 2009 ... healthcare communications company. The board provides guidance on innovative ways to leverage PerfectServe,s physician-contact ...
... PITTSBURGH, Sept. 17 DynaVox Mayer-Johnson, the world,s ... speech, language and learning disabilities, today announced the company received ... Microsoft Corp. This award recognizes DynaVox Mayer-Johnson for its ... products. , , "We are proud to ...
... LANSING, Mich., Sept. 17 Neogen Corporation (Nasdaq: NEOG ) announces the ... Neogen Corporation 1st Quarter Results Webcast, When: Thursday, September ... How: Live over the Internet -- Simply log on to ... Address above., Contact: Terry Maynard of Neogen Corporation, +1-800-234-5333., , ...
... Chief Operating Officer and Future CEO , , TORONTO, ... MDZ ), a leading provider of products and services ... West, President of MDS Nordion, has been appointed Chief Operating ... Chief Executive Officer of MDS Inc., intends to step down ...
... NEW YORK, Sept. 17 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) ... that develops novel therapeutic proteins that disrupt the ... signed a collaboration deal with Beckpharma Ltd. ("Beckpharma") ... treatments. , The two companies are joining forces ...
Cached Medicine News:Health News:Even Small Amounts of Lead Harmful to Kids 2Health News:Even Small Amounts of Lead Harmful to Kids 3Health News:Alan Weinstein Named Chairman of PerfectServe Advisory Board 2Health News:DynaVox Mayer-Johnson Receives Microsoft Award 2Health News:MDS Announces CEO Transition Plan 2Health News:MDS Announces CEO Transition Plan 3Health News:MDS Announces CEO Transition Plan 4Health News:GENova Biotherapeutics secures new cancer drugs targets 2Health News:GENova Biotherapeutics secures new cancer drugs targets 3
... Professional Diagnostics is a leading provider of ... DFA test menu that includes kits for ... well as miscellaneous conjugates and components. Our ... wide assortment of substrates and kit sizes ...
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
... Professional Diagnostics is a leading provider of ... DFA test menu that includes kits for ... well as miscellaneous conjugates and components. Our ... wide assortment of substrates and kit sizes ...
... a leading provider of immunofluorescence assays, with ... that includes kits for autoimmune diseases, infectious ... conjugates and components. Our Impact IFA Test ... substrates and kit sizes to choose from. ...
Medicine Products: